Previous 10 | Next 10 |
Therapeutic and diagnostic Morphomers™ enable AC Immune’s unique precision medicine approach for neurodegenerative diseases Webinar will take place on Wednesday, March 31, 2020 at 10:00 AM ET LAUSANNE, Switzerland, March 26, 2021 (GLOBE NEWSWIRE) -- A...
ACIU is developing drugs for Alzheimer's disease. They have some cash and a lot of partnerships. However, amyloid plaque removal is not a novel hypothesis. For further details see: AC Immune: Old Theory, New Company
AC Immune (ACIU): FY Non-GAAP EPS of -CHF0.79 misses by CHF0.02; GAAP EPS of -CHF0.86 misses by CHF0.04.Revenue of CHF15.4M (-86.1% Y/Y) misses by CHF0.37M.FY2021 guidance: Total cash burn to range between CHF 65M-75M.Press Release For further details see: AC Immune EPS misses by ...
Anti-pTau Alzheimer’s vaccine delivers potent immunogenicity in ongoing Phase 1b/2a study, supporting further development into Phase 2/3 Anti-Abeta Alzheimer’s vaccine advancing based on Phase 1b safety and immunogenicity results in Down syndrome; further interim res...
AC Immune SA (ACIU) announces plans to advance its novel anti-amyloid-beta (Abeta) vaccine into mid-stage clinical testing to treat and prevent the progression of Down syndrome ((DS))-related Alzheimer’s disease ((AD)).Topline results showed that ACI-24 showed encouraging immunogenicit...
Topline ACI-24 Phase 1b immunogenicity and safety results reported today at a global Down syndrome symposium Reported new data in non-human primates for optimized vaccine formulation which shows strong response against key pathological Abeta species, including oligomeric and pyr...
AC Immune (ACIU) has outlined new preclinical data that will be presented at the 15th International Conference on Alzheimer’s & Parkinson’s Diseases, taking place from March 9–14, 2021.Data from the Company’s therapeutic and diagnostic programs targeting pathol...
Four presentations at AD/PD™ 2021 feature latest findings from wholly owned therapeutic and diagnostic programs targeting pathological forms of alpha-synuclein and TDP-43 First biologically active small molecule inhibitors of intracellular alpha-synuclein aggregation ...
LAUSANNE, Switzerland, Feb. 24, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that four new data presentations will be delivered at the 15 th Inte...
LAUSANNE, Switzerland, Feb. 17, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will participate in the upcoming SVB Leerink 10 th Annual Gl...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...